ClinicalTrials.gg
RecruitingNCT06571721Updated Aug 28, 2024

The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles

An interventional study of Topical Product: Almond Oil and Topical Product: Almond oil augmented with 0.5% Vitamin E in Collagen Degeneration, Wrinkle and Pigmentation, sponsored by Integrative Skin Science and Research. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by Integrative Skin Science and Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Ehlers-Danlos Syndrome with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ehlers-Danlos Syndrome · United States.

Planned enrollment
6th of 15
90 · median 60
Started
2024
with 3 others
No phase
13 of 26
7 open now
Primary completion
2025-01
later than 1 of 10 live
Registered
21st of 26
by date
Lead sponsor
2 of 26
Integrative Skin Science and Research

Among the 26 studies in Ehlers-Danlos Syndrome with a site in United States, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2024, is one of 13 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 21st registered.

Ehlers-Danlos Syndrome

67 studies on the registry are indexed under Ehlers-Danlos Syndrome; 24 are open to participants now.

Browse Ehlers-Danlos Syndrome studies →

Open to participants now

9 of the 26 studies in Ehlers-Danlos Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Ehlers-Danlos Syndrome studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Ehlers-Danlos Syndrome with a site in United States, or all of them as a file.
02

Study summary

Investigate the topical use of almond oil, almond oil augmented with 0.5% vitamin E, 0.025% tretinoin oil augmented with castor oil on the appearance of facial fine lines and wrinkles, pigmentation, hydration, trans-epidermal water loss, and sebum excretion rate.

Read the detailed description

The natural cosmetic market is a multi-billion dollar industry. Nutraceuticals and food-based cosmetics are a growing trend within dermatology. Almonds are a rich dietary source of a range of fatty acids, phytochemical polyphenols, and antioxidants. Our previous study was a double blinded study that compared almond consumption interventions to a calorie matched intervention over 16 weeks. The study determined that that there was a statistically significant 8.41% improvement in wrinkle severity in the women that received almond supplementation. This proposal aims to now understand how the topical application of almond oil may influence the appearance of wrinkles and facial tone in post-menopausal women. Almond oil is rich in fatty acids and alpha-tocopherol. Tocopherol inhibits melanogenesis in melanocytes and topical alpha tocopherol has been shown to improve skin antioxidants and hyperpigmentation. A challenge of almond oil is that it is prone to oxidation due to its high unsaturated fatty acid concentrations. However, tocopherol has also been shown to improve almond oil stability.

03

Conditions studied

  • Collagen Degeneration
  • Wrinkle
  • Pigmentation
  • Elastic Skin
  • Sebum Deficiency

Browse trials for

Keywords

  • Facial Wrinkles
  • Skin biophysical properties
  • Photoaging
  • Pigmentation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women of Fitzpatrick skin types 1, 2, and 3
  • Individuals with facial fine lines and wrinkles

Exclusion criteria

Exclusion Criteria:

  • Individuals who are pregnant or breastfeeding
  • Prisoners
  • Adults unable to consent
  • Those with a nut allergy or tocopherol allergy
  • Current smokers, those that have smoked within the past year, and former smokers with greater than a 10-pack- year history of smoking
  • Those with an photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndromes)
  • Those who have undergone any cosmetic procedures to the face in the 3 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment
  • Individuals who are unwilling to discontinue vitamin E containing supplements and food sources such as all nuts, sunflower seeds or sunflower oil during the and intervention
  • Individual who are unwilling to discontinue topical cosmetic products during the duration of the study or unwilling to undergo a 2-week washout of topicals that are known to modulate collagen and pigment:
  • Retinoids such as tretinoin, adapalene, retinol, except as provided by the study.
  • Antioxidant ingredients such as vitamin C or vitamin E.
  • Pigment reducing agents such as hydroquinone, azelaic acid, kojic acid, or a retinoid except for the retinol that is provided in this study.
  • Topicals that contain a nut oil or nut extract as part of their ingredient list.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Almond Oil

    Almond Oil. 1-2 Drops of randomized topical product will be applied on entire face nightly. Duration: 16 weeks

    Other: Topical Product: Almond Oil

  • Experimental
    Almond oil augmented with 0.5% Vitamin E

    Almond oil augmented with 0.5% Vitamin E. 1-2 Drops of randomized topical product will be applied on entire face nightly. Duration: 16 weeks

    Other: Topical Product: Almond oil augmented with 0.5% Vitamin E

  • Experimental
    0.025% Tretinoin oil augmented with castor oil

    0.025% Tretinoin oil augmented with castor oil. 1-2 Drops of randomized topical product will be applied on entire face nightly. Duration: 16 weeks

    Other: Topical Product: 0.025% Tretinoin oil augmented with castor oil

Interventions

  • OtherTopical Product: Almond Oil

    1-2 Drops of randomized topical product will be applied on entire face nightly.

  • OtherTopical Product: Almond oil augmented with 0.5% Vitamin E

    1-2 Drops of randomized topical product will be applied on entire face nightly.

  • OtherTopical Product: 0.025% Tretinoin oil augmented with castor oil

    1-2 Drops of randomized topical product will be applied on entire face nightly.

06

What researchers measure

Primary outcomes

  1. Facial wrinkles

    Change in severity of wrinkles measured by photographic analysis (BTBP 3D Camera System)

    Time frame: 16 Weeks

Secondary outcomes

  1. Changes in Pigment intensity through the use of high resolution photography (BTBP Clarity Pro)

    Change in the appearance of facial pigmentation by high resolution photography (BTBP Clarity Pro) and measures intensity of facial pigmentation. Higher scores indicate darker pigmentation.

    Time frame: 16 Weeks

  2. Pigment intensity measured through SkinColorCatch.

    Change in the appearance of facial pigmentation will be measured on both cheeks through the use of a handheld device known as the SkinColorCatch with quantitative output for pigment intensity.

    Time frame: 16 Weeks

  3. Changes in skin hydration

    Change in skin hydration will be measured on both cheeks through the use of a non-invasive device known as the Moisturemeter.

    Time frame: 16 Weeks

  4. Sebum excretion rate

    Measure of skin sebum via sebumeter

    Time frame: 16 Weeks

  5. Tolerability Assessment Questionnaire

    A 6 question survey based on the self-assessment about the tolerability of the topical skin product. The scale ranges from 0-3 with 0 being the best outcome possible and with 3 being the worst. "0" as none, "1" as mild, "2" as moderate, or "3" as severe.

    Time frame: 16 Weeks

  6. Transepidermal water loss

    Change in transepidermal water loss (TEWL) using the Vapometer

    Time frame: 16 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jan 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 26, 2024
StartActual
Jul 22, 2024
Primary completionEst.
Jan 22, 2025
CompletionEst.
Jul 22, 2025
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06571721
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Jul 22, 2024
Primary completion
Jan 22, 2025 (estimated)
Completion
Jul 22, 2025 (estimated)
Last update
Aug 28, 2024

Study contacts

Nasima Afzal
Contact
nasima@integrativeskinresearch.com
915-750-2463

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion